Loading...
Patients with high-risk localized kidney cancer after nephrectomy have a high rate of systemic recurrence. Investigators of the industry-sponsored, randomized 3 KEYNOTE-564 trial previously reported a statistically and clinically significant improvement in disease-free survival in patients with clear-cell renal-cell carcinoma and high-risk pathology managed with 1 year of adjuvant pembrolizumab compared to placebo. At the time of the initial report, at a median follow-up of 24 months, data for overall survival were immature. Now, the investigators report results at a median follow-up of 57 months.
Of nearly 1000 participants, the estimated percentage who were alive at 48 months was 91.2% in the pembrolizumab group and 86.0% in the placebo gr…